Enovis (NYSE:ENOV) Share Price Breaks Below 50-Day Moving Average – Should You Sell?

Enovis Corporation (NYSE:ENOV)’s stock price passed below its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $20.02 and traded as low as $19.83. Enovis shares last traded at $19.92, with a volume of 2,524,526 shares.

Wall Street Analyst Weigh In

ENOV has been the topic of several research reports. Canaccord Genuity Group cut their target price on Enovis from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Monday, August 17th. Wells Fargo & Company decreased their target price on Enovis from $39.00 to $33.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 2nd. Zacks Research raised shares of Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Citigroup restated a “market outperform” rating on shares of Enovis in a research note on Wednesday, September 2nd. Finally, Wall Street Zen raised shares of Enovis from a “hold” rating to a “buy” rating in a report on Saturday. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Enovis currently has an average rating of “Moderate Buy” and a consensus price target of $37.25.

Enovis Trading Down 12.7%

The company has a market capitalization of $1.15 billion, a price-to-earnings ratio of -1.03 and a beta of 1.37. The business’s 50 day moving average price is $20.02 and its two-hundred day moving average price is $23.08. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.00 and a current ratio of 1.98.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.05. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%. The company had revenue of $582.78 million for the quarter, compared to analyst estimates of $581.84 million. During the same period in the prior year, the firm posted $0.79 EPS. The business’s revenue was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities analysts forecast that Enovis Corporation will post 3.15 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Damien Mcdonald bought 13,035 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was purchased at an average cost of $19.15 per share, for a total transaction of $249,620.25. Following the transaction, the chief executive officer owned 247,077 shares in the company, valued at $4,731,524.55. The trade was a 5.57% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Oliver Engert purchased 2,660 shares of the company’s stock in a transaction dated Friday, September 4th. The stock was purchased at an average price of $18.80 per share, with a total value of $50,008.00. Following the completion of the purchase, the insider directly owned 63,898 shares in the company, valued at $1,201,282.40. The trade was a 4.34% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders purchased 23,293 shares of company stock worth $449,599. 2.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Enovis

A number of institutional investors have recently added to or reduced their stakes in the company. Paradigm Capital Management Inc. NY boosted its stake in Enovis by 70.2% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock valued at $40,420,000 after purchasing an additional 732,917 shares during the last quarter. Private Management Group Inc. raised its holdings in Enovis by 38.8% during the second quarter. Private Management Group Inc. now owns 1,365,082 shares of the company’s stock valued at $28,257,000 after acquiring an additional 381,705 shares during the period. Allspring Global Investments Holdings LLC grew its position in shares of Enovis by 38.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 1,045,360 shares of the company’s stock worth $24,430,000 after purchasing an additional 287,687 shares in the last quarter. Front Street Capital Management Inc. grew its holdings in Enovis by 106.1% during the 1st quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock valued at $16,973,000 after buying an additional 384,124 shares in the last quarter. Finally, Quantinno Capital Management LP grew its stake in Enovis by 130.8% during the first quarter. Quantinno Capital Management LP now owns 604,500 shares of the company’s stock valued at $13,752,000 after acquiring an additional 342,556 shares in the last quarter. 98.45% of the stock is owned by institutional investors.

Enovis Company Profile

Enovis Corporation (NYSE: ENOV) is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company’s products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.